Dive Brief:
- Integra Lifesciences, a maker of surgical instruments and tissue regeneration technologies, has notified Indiana that it will close a manufacturing facility in Lafayette in late April, affecting 60 workers.
- Most of the plant’s employees will be laid off by April 26, with eight people expected to see their employment end by May 31, according to a Feb. 13 Worker Adjustment and Retraining Notification notice on the Indiana Department of Workforce Development’s website. One employee will continue in a remote role, according to an Integra spokesperson.
- The company plans to relocate manufacturing of tissue products and technologies for hernia, abdominal wall repair and wound reconstruction from the Lafayette plant to a facility in Columbia, Maryland, as part of an overall effort to strengthen operational efficiency, the spokesperson told MedTech Dive Tuesday in an email.
Dive Insight:
Integra has been working to resolve a July 2023 warning letter from the Food and Drug Administration that identified quality issues at the company’s Boston manufacturing plant, where it produces collagen-based medical devices for wound care, soft tissue repair and reconstruction surgery.
The warning letter followed Integra’s recall in May 2023 of all products made at the Boston facility dating back more than five years. Integra initially paused production at the site in December 2022 after an internal quality complaint.
The company lowered its full-year 2023 revenue forecast in July and again in October to reflect the impact of the recall for products made at the Boston site.
The Princeton, New Jersey-based company restarted the Boston factory in mid-November 2023 and expects to resume distribution of products made there in the mid- to late-second quarter of this year, Integra’s spokesperson said.
The Indiana plant shutdown is the only facility closure happening at this time, the spokesperson noted.
In December, Integra said it agreed to acquire the Acclarent ear, nose and throat device business from Johnson & Johnson for $275 million.
Integra is scheduled to report its fourth-quarter and full-year 2023 financial results on Wednesday.
